Research Pulse — 2026-08-25 | Brown Biotech

# Research Pulse — 2026-08-25
_Generated 2026-08-25 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 8월 25일 (화요일) · Optimizing(최적화 Day)**

8/25(최적화)→8/24(Transitioning)→8/23(Validating)→8/22(Assessing)→8/21(Scanning)→8/20(Expanding)→8/19(Diversifying)→8/18(Converging)→...→7/14(가속). Transitioning(8/24)된 기술들이 **산업화 조건 충족 후 자원 최적화·효율화·정밀화로 전환(Optimizing)하는 날** — LuT lipids로 WHO Lung-targeting LNP delivery 시스템 구축으로 비간 표적 Organ-Targeting 체계 최적화(Tian Nature Biomedical Engineering 2026), CICS single-particle 분석으로 LNP payload distribution quality attributes와 gene editing potency 상관관계 정량화(Truong Molecular Therapy 2026), CellxPert inference-time MCMC steering로 multi-omics foundation model perturbation prediction 정밀화(Demir ArXiv 2026), spatial ecotypes가 cfDNA deep learning으로 immunotherapy response 예측 가능성 확인(Zhang Nature 2026), AlphaFold의 protein-ligand data 부족 문제로 drug discovery 적용边界 한계 정립(Singh Current Opinion Structural Biology 2026), 2026년 FDA pipeline 52개 novel drugs 예상(Dean AJHP 2026)이 동시에 진행된다.

Optimizing은 Transitioning의 다음 단계다. 오늘 6개 전선은 산업화 체계가 확립된 기술들이 **자원 효율화·정밀 예측·최적 배치를 통해 성능을 최적화하는 날**이다.

*출처: [Tian LuT Lipids Nature Biomedical Engineering 2026](https://consensus.app/papers/details/58273e5a294453e4b49033311d6f6192/), [Truong CICS LNP Molecular Therapy 2026](https://consensus.app/papers/details/31a186a2826b5b9f9eb8c87ed71a040c/), [Demir CellxPert ArXiv 2026](https://consensus.app/papers/details/32110de5fa6651398632ec116e93577d/), [Zhang Spatial Ecotypes Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Singh AlphaFold Protein-Ligand Data Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Dean FDA Pipeline AJHP 2026](https://consensus.app/papers/details/780421396729574383a4c7cfcb479acb/)*

*#OptimizingDay #Tian #LuTLipids #NatureBiomedicalEngineering #LungTargeting #LNP #TripodLike #90PercentSelectivity #Truong #CICS #MolecularTherapy #PayloadDistribution #GeneEditing #Potency #Demir #CellxPert #MCMC #FoundationModel #Perturbation #Zhang #SpatialEcotypes #Nature #cfDNA #Immunotherapy #Singh #AlphaFold #ProteinLigand #CurrentOpinion #Dean #AJHP #FDA2026 #52Drugs #Optimizing #Transitioning #ResourceOptimization #PrecisionDelivery #PerturbationPrediction #OrganTargeting #LNPDesign*

---

### Post 2: CRISPR & Gene Editing — LuT Lipids Lung-Targeting 체계와 CICS LNP Payload Distribution 최적화

🧪 **[CRISPR/Gene Editing] LuT lipids로 25.5배 개선된 lung-targeting LNP delivery 체계 구축으로 90% 이상 폐 표적 달성(Tian Nature Biomedical Engineering 2026) + CICS single-particle 분석으로 LNP payload distribution quality attributes와 gene editing potency 상관관계 정량화(Truong Molecular Therapy 2026) + LNP immune cell engineering 적용 확대 종합(Ciganek Materials Today Bio 2026): Organ-Targeting LNP 최적화 동시 확인**

CRISPR/LNP 전달 기술의**최적화 체계**가 출처에서 동시에 확인된다[1][2][3].

**LuT Lung-Targeting Lipids: 'Tripod-Like' 구조로 90% 폐 표적 달성[1]**
Zeru Tian et al.(Nature Biomedical Engineering 2026)의 연구는 444개 LuT lipids를 합성·평가하여 lung-targeting LNP delivery 체계를 구축한다. **Tripod-like 구조의 우위**: quaternary amine head + 3개 long alkyl chains(legs) + short chain(handle)으로 기존 lung-targeting lipids와 구조적으로 차별화. **Lead 1A7B13 LNPs 성과**: mRNA 전달 25.5배 개선, CRISPR-Cas9 gene editing 9.2배 개선(DOTAP SORT LNPs 대비). **90% 이상 폐 선택성**: selectivity 달성. **Mechanism**: endosomal escape 개선 + cargo release 촉진 + plasma protein adsorption을 통한 endogenous targeting. **생존률 개선 확인**: acute lung injury 모델에서 IL-10 mRNA 전달로 치료 효과 확인. 핵심: LuT lipids로 tripod-like 구조 기반 lung-targeting LNP 체계 구축 — 비간 표적 최적화의里程碑.

**CICS Single-Particle Analysis: LNP Payload Distribution과 Gene Editing Potency 상관관계 정량화[2]**
Linh B. Truong et al.(Molecular Therapy 2026)의 연구는 CICS(cylindrical illumination confocal spectroscopy)로 LNP payload distribution을 single-particle 수준에서 분석한다. **4개 subpopulations 발견**: co-encapsulated(50.7-60.4%), gRNA only(30.0-36.5%), mRNA only(2.0-3.4%), empty(4.2-13.8%). **Payload distribution이 potency 결정**: higher cargo loads(9.8 vs 8.0 mRNA copies, 25.4 vs 20.3 gRNA copies per particle)에서 1.5배 높은 in vivo editing(55.4% vs 36.3% indels). **핵심 인사이트**: biophysical characteristics(size, encapsulation) 거의 동일하나 payload distribution 차이로 编辑 효율 결정. 핵심: CICS single-particle 분석으로 LNP payload distribution quality attributes 정량화 — delivery optimization의 정밀화.

**LNP Immune Cell Engineering: CRISPR Immune Cell Programming 적용 확대[3]**
Ivan Ciganek et al.(Materials Today Bio 2026)의 review는 LNP 기반 CRISPR immune cell engineering의 현재 상태를 종합한다. **Viral vectors의 한계**: immunogenicity, genomic integration, manufacturing scalability 문제. **LNP의 우위**: clinically validated, scalable, biocompatible. **최신 혁신**: selective organ targeting(SORT), ligand conjugation, sequence-level translational control. **현재 도전**: suboptimal endosomal escape, extrahepatic targeting, PEG dilemma. 핵심: LNP immune cell engineering 적용 확대 종합 — CRISPR immune engineering의 최적화 경로.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Janjuha Nature Biomedical Engineering**으로 **ISS spatial profiling mice·macaques 확산**을, **Froechlich Molecular Therapy**으로 **mRNA/LNP vaccine de-targeting**을, **Tálas Science Translational Medicine**으로 **RNA-LNP PE7 CTLN1 치료**를 제시했다면, 오늘은 **Tian Nature Biomedical Engineering**으로 **LuT lipids tripod-like 90% lung targeting 달성**을(정밀 Organ-Targeting), **Truong Molecular Therapy**으로 **CICS로 payload distribution-编辑 potency 상관관계 정량화**를(quality optimization), **Ciganek Materials Today Bio**로 **LNP immune cell engineering 적용 확대**를(immune engineering 최적화) 동시에 제시한다. Expanding(8/20) → Organ-Targeting 정밀화 + quality attributes 최적화 Optimizing(8/25).

실무 함의: 폐 질환 유전자 치료 전달팀에서 Tian et al.의 LuT lipids 결과를 분석하여 lung-targeting strategy를 수립해야 한다.

*출처: [Tian LuT Lung-Targeting Lipids Nature Biomedical Engineering 2026](https://consensus.app/papers/details/58273e5a294453e4b49033311d6f6192/), [Truong CICS LNP Payload Distribution Molecular Therapy 2026](https://consensus.app/papers/details/31a186a2826b5b9f9eb8c87ed71a040c/), [Ciganek LNP Immune Cell Engineering Materials Today Bio 2026](https://consensus.app/papers/details/48353b932e435fcc94a00ac93469e299/)*

*#CRISPR #GeneEditing #Tian #LuTLipids #NatureBiomedicalEngineering #LungTargeting #TripodLike #90PercentSelectivity #Truong #CICS #MolecularTherapy #PayloadDistribution #Indels #GeneEditingPotency #Ciganek #MaterialsTodayBio #LNPMultiomics #ImmuneCellEngineering #PEG #EndosomalEscape #OptimizingDay #OrganTargeting #LNPDesign #QualityControl #SingleParticle #mRNADelivery #CRISPRCas9 #AcuteLungInjury #DOTAP #Sort lipid*

---

### Post 3: AI 신약 — AI Drug Discovery 임상 이행 현실과 Phase IIa candidate现身

💊 **[AI 신약] AI drug discovery의 임상 이행 현실 분석 — Phase IIa efficacy 확인과 Phase I safety 문제 동시 출현(Mao Frontiers Pharmacology 2026) + AlphaFold protein-ligand data 부족으로 drug discovery 적용 boundary 한계 정립(Singh Current Opinion Structural Biology 2026) + 2026년 FDA pipeline 52개 novel drugs 예상으로 AI-Discovered candidates 현황 진단(Dean AJHP 2026): AI drug discovery의 최적화 단계 현실 동시 확인**

AI-Driven Drug Discovery의**최적화 단계 현실**이 출처에서 동시에 확인된다[4][5][6].

**AI Drug Discovery 임상 이행 현실: Double-Edged Sword[4]**
Zihan Mao et al.(Frontiers in Pharmacology 2026)의 review는 2007-2026년 literature로 AI drug discovery의 임상 이행 현실을 분석한다. **Phase IIa efficacy 확인**: AI-discovered candidates 중 Phase IIa에서 encouraging efficacy 확인된 사례 존재. **Phase I safety 문제**: 다른 candidate은 Phase I에서 safety signals로 중단. **AI의 제약**: biological complexity, patchy data, ML + pharmaceutics combined fluency 부족. **향후 방향**: multimodal data integration + explainable AI(XAI)가 regulatory confidence를 위해 필수. **Traditional Chinese Medicine과 natural product screening으로 확장**. 핵심: AI drug discovery 임상 이행 현실 — efficacy 확인과 safety 문제 동시 존재하는 double-edged sword.

**AlphaFold Protein-Ligand Data 부족: Drug Discovery 적용 Boundary 한계 정립[5]**
Sukrit Singh et al.(Current Opinion in Structural Biology 2026)의 review는 AlphaFold-like models의 protein-ligand data 부족 문제를 분석한다. **SBDD의 도전**: AlphaFold가 protein structure prediction 혁신 이루었으나, drug discovery 적용에는 한계. **핵심 문제**: AlphaFold-like models는 training data에 의존 — protein-ligand complex data insufficient. **hierarchical framework 제시**: 어떤 task에서 현재 모델이 잘 수행하는지 vs challenging/unexplored task 구분. **향후 방향**: systematic dataset generation 필요 — experimental + physics-based datasets 생성으로 frontier model 개발 지원. 핵심: AlphaFold protein-ligand data 부족으로 drug discovery 적용 boundary 한계 정립 — computational-experimental integration 최적화 필요.

**2026년 FDA Pipeline: 52개 Novel Drugs 예상과 AI-Discovered Candidates 현황[6]**
Collin Dean et al.(AJHP 2026)의 review는 2026년 FDA novel drug approvals pipeline을 예측한다. **Pipeline 규모**: 52개 novel drugs FDA 승인 대기. **치료 영역**: rare/inherited genetic disorders, immunologic/inflammatory diseases, targeted oncology, gene therapies. **AI-Discovered candidates 포함**: pipeline 내 AI-assisted разработка 포함. **관심 약물**: novel therapies for various disease states. 핵심: 2026년 FDA 52개 novel drugs 예상 — AI-Discovered candidates pipeline 내 현황 진단.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Zhang DrugCLIP**으로 **contrastive learning ultrafast genome-wide screening**을, **Raghupathi Health Information Science Systems**으로 **4Vs → veracity/validity/viability framework 확장**을, **de Oliveira Teixeira AlphaFold AMR**로 **antibiotic resistance target discovery**를 제시했다면, 오늘은 **Mao Frontiers Pharmacology**으로 **AI clinical translation Phase IIa efficacy + Phase I safety 동시 출현**을( 임상 이행 현실), **Singh Current Opinion**으로 **AlphaFold protein-ligand data 부족으로 적용 boundary 한계**를(기술적 한계 인식), **Dean AJHP**으로 **2026년 FDA 52개 novel drugs 예상**을(pipeline 현황) 동시에 제시한다. Expanding(8/20) → 임상 이행 현실 + 적용 boundary 한계 정립 + pipeline 현황 Optimizing(8/25).

실무 함의: AI drug discovery 협업팀에서 Mao et al.의 clinical translation 현실 분석을 참조하여 realistic pipeline expectation을 수립해야 한다.

*출처: [Mao AI Drug Discovery Clinical Translation Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Singh AlphaFold Protein-Ligand Data Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Dean FDA Pipeline AJHP 2026](https://consensus.app/papers/details/780421396729574383a4c7cfcb479acb/)*

*#AI #DrugDiscovery #Mao #FrontiersPharmacology #PhaseIIa #PhaseI #SafetySignals #ClinicalTranslation #DoubleEdged #Singh #AlphaFold #ProteinLigand #CurrentOpinion #StructuralBiology #SBDD #DataGap #Dean #AJHP #FDA2026 #52Drugs #Pipeline #OptimizingDay #AIIntegration #ExplainableAI #XAI #Regulatory #Multimodal #NaturalProducts #TCM #DrugDesign*

---

### Post 4: 단백질 AI — AlphaFold Mutation Invariance 문제와 Drug Discovery 적용边界 정리

🔬 **[단백질 AI] AlphaFold adversarial mutations에서 40% 잔기 치환에도 구조 불변 확인으로 template-based pattern matching 의존성 문제 확인(Feldman Computational Biotechnology 2026) + AlphaFold drug discovery 적용의 disease understanding · vaccine design · drug repurposing 전체 맥락 종합(Kinde Results Engineering 2026) + AlphaFold-like models protein-ligand data 부족으로 적용 boundary 한계 정립(Singh Current Opinion Structural Biology 2026): 단백질 AI의 최적화 단계 적용 boundary 정리 동시 확인**

단백질 AI의**최적화 단계 적용 boundary 정리**가 출처에서 동시에 확인된다[7][8][9].

**AlphaFold Mutation Invariance: Template-Based Pattern Matching 의존성 문제 확인[7]**
Jonathan Feldman et al.(Computational and Structural Biotechnology Journal 2026)의 연구는 AlphaFold3의 adversarial mutation 평가를 수행한다. **40% 잔기 치환에도 구조 불변**: 의도적 탈안정화 치환에서도 예측 구조 유지. **10% 잔기 결여에도 불변**: fold-switching proteins에서도 마찬가지. **가장 정확한 구조 35% 이하에서만 선택**: confidence metrics 불신뢰. **ESMFold 상대적 우위**: 더 높은(완벽하지 않은) mutation sensitivity. **핵심 문제**: AlphaFold가 biophysical reasoning보다 template-based pattern matching에 의존. **Implication**: mutation-effect interpretation, confidence-guided model selection, sequence optimization workflows에 직접적 영향. 핵심: AlphaFold mutation invariance 문제로 template-based pattern matching 의존성 확인 — de novo protein design 해석 주의 필요.

**AlphaFold Applications 종합: Disease Understanding · Vaccine Design · Drug Repurposing[8]**
M. Kinde et al.(Results in Engineering 2026)의 review는 AlphaFold의 drug discovery 적용을 종합한다. **질병 이해**: disease mechanism阐明, genetic variants의 structural consequences 분석. **약물 발견**: target identification → toxicity prediction까지 전 단계 적용. **약물 재배치**: drug repurposing 가속화. **Vaccine design**: pathogen proteins의 상세 구조 제공. **한계**: computational power, disordered proteins, conformational changes, experimental methods integration. 핵심: AlphaFold drug discovery 적용 전체 맥락 종합 — 적용 범위와 한계 동시 인식.

**AlphaFold Protein-Ligand Data Gap: 적용 Boundary 한계 정립[9]**
Sukrit Singh et al.(Current Opinion in Structural Biology 2026)의 review는 AlphaFold-like models의 protein-ligand data不足 문제를 분석한다. **SBDD의 도전**: structure-based drug design에서 AlphaFold 적용의 한계. **핵심**: protein-ligand complex data insufficient → drug discovery task에서 성능 제한. **hierarchical framework**: current models의 수행 가능한 task vs challenging/unexplored task 구분. **향후**: systematic dataset generation으로 frontier model 개발 지원 필요. 핵심: AlphaFold protein-ligand data 부족으로 drug discovery 적용 boundary 한계 정립 — computational-experimental integration 최적화 방향 제시.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **de Oliveira Teixeira Journal Computer-Aided Molecular Design**으로 **AlphaFold structures antibiotic resistance target discovery**를, **Tortolani Biochemical Pharmacology**으로 **GPR18 AlphaFold modeling neuroinflammatory disorders**를, **Dhir RSC Advances**로 **AI drug design workflow 포괄적 종합**을 제시했다면, 오늘은 **Feldman Computational Biotechnology**으로 **AlphaFold mutation invariance template-based 패턴 의존성**을(기술적 한계), **Kinde Results Engineering**으로 **AlphaFold drug discovery 전체 맥락 종합**을(적용 범위), **Singh Current Opinion**으로 **protein-ligand data 부족으로 적용 boundary**를(최적화 boundary) 동시에 제시한다. Expanding(8/20) → 기술적 한계 인식 + 적용 범위 종합 + boundary 정립 Optimizing(8/25).

실무 함의: 전산단백질 설계팀에서 Feldman et al.의 mutation invariance 결과를 분석하여 AlphaFold 적용 시 confidence evaluation protocol을 수립해야 한다.

*출처: [Feldman AlphaFold Mutation Invariance Computational Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Kinde AlphaFold Applications Results Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/), [Singh AlphaFold Protein-Ligand Data Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)*

*#ProteinAI #AlphaFold #Feldman #ComputationalBiotechnology #MutationInvariance #TemplateBased #PatternMatching #ESMFold #Kinde #ResultsEngineering #DrugDiscovery #VaccineDesign #DrugRepurposing #Singh #CurrentOpinion #StructuralBiology #ProteinLigand #DataGap #SBDD #OptimizingDay #ConfidenceMetrics #FoldSwitching #MutationSensitivity #DeNovoProtein #ProteinDesign #BiophysicalReasoning*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — CellxPert MCMC Steering와 Scaling Laws 도전

🬬 **[Single-Cell Multi-Omics Foundation Model] CellxPert inference-time MCMC steering로 multi-omics foundation model perturbation prediction 정밀화(Demir ArXiv 2026) + Geneformer·scGPT scaling laws 도전 확인 — perturbation prediction에서 단순 summary statistics 이상 포착 어려움(Yan BMC Genomics 2026) + scFMs의 unification toward mechanistic understanding 포괄적 review(Dimitrov Nature Reviews Genetics 2026): foundation model의 최적화 단계 동시 확인**

Single-Cell Foundation Model의**최적화 단계**가 출처에서 동시에 확인된다[10][11][12].

**CellxPert: Inference-Time MCMC Steering로 Perturbation Prediction 정밀화[10]**
Andac Demir et al.(ArXiv 2026)의 연구는 CellxPert를 제시한다. **Joint encoding**: scRNA-seq + ATAC-seq + CITE-seq + MERFISH + imaging mass cytometry 통합. **4개 downstream tasks**: cell-type annotation(154개 label), LoRA fine-tuning, genome-wide ISP(perturbation prediction), multi-omics integration. **MCMC steering의 혁신**: Metropolis-Hasticks sampler로 model's masked conditional distributions 사용 → abrupt token manipulation의 OOD artifacts 완화. ** biologically interpretable trajectories**: canonical signaling pathways와 context-dependent transcriptional cascades 회복. **Benchmark results**: PBMC68K, Replogle Perturb-seq, Systema, BMMC에서 state-of-the-art 상회. 핵심: CellxPert inference-time MCMC steering로 multi-omics foundation model perturbation prediction 정밀화 — inference-time optimization의 새 paradigm.

**Geneformer·scGPT Scaling Laws 도전: Perturbation Prediction에서 Simple Summary Statistics 이상 포착 어려움[11]**
Yuhai Yan et al.(BMC Genomics 2026)의 연구는 scFMs의 scaling laws를 평가한다. **Task dependency**: large-scale pretraining benefits가 cell type annotation에서는 substantial하나 perturbation prediction에서는 limited. **Model size 증가 ≠ 성능 향상**: perturbation prediction에서는 오히려 detrimental. **"Bigger is better" paradigm 도전**: tested models and tasks에서 확인. **심각한 발견**: perturbation prediction에서 scFMs가 simple summary statistics 이상 포착 어려움 → complex biological interactions 학습 제한. **미래 방향**: task-specific architectures + biologically-informed priors 통합 필요. 핵심: scFMs scaling laws 도전으로 perturbation prediction 한계 확인 — foundation model 최적화 방향 제시.

**scFMs Unification toward Mechanistic Understanding: 포괄적 Review[12]**
Daniel Dimitrov et al.(Nature Reviews Genetics 2026)의 review는 single-cell analyses의 방향을 종합한다. **Descriptive atlasing → causal inference로 전환**: mechanistic relationships 포착. **5개 modeling concepts**: representation learning, causal inference, mechanistic discovery, disentanglement, population tracing. **unifying ontology 제시**: practitioners가 biological question에 가장 적합한 방법론 선택 지원. **computational directions**: underexplored data properties 활용으로 future developments 제시. 핵심: scFMs의 unification toward mechanistic understanding — 기술 최적화 단계의 conceptual framework.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Kendiukhov Computational Biology Chemistry**으로 **adversarial validation framework 확립**을, **Abir NAR Genomics Bioinformatics**으로 **CFM-GP conditional flow matching**을, **Fan Synthetic Systems Biotechnology**으로 **scYeast biological-knowledge-guided**를 제시했다면, 오늘은 **Demir ArXiv**으로 **CellxPert MCMC steering로 perturbation prediction 정밀화**를(inference optimization), **Yan BMC Genomics**으로 **scaling laws 도전으로 perturbation prediction 한계**를(기술적 한계), **Dimitrov Nature Reviews Genetics**으로 **mechanistic understanding으로 unification**을(conceptual framework) 동시에 제시한다. Expanding(8/20) → inference optimization + scaling limitation + conceptual framework Optimizing(8/25).

실무 함의: 단일세포 연구팀에서 Yan et al.의 scaling laws 결과를 분석하여 perturbation prediction 적용 시 biologically-informed priors 전략을 수립해야 한다.

*출처: [Demir CellxPert ArXiv 2026](https://consensus.app/papers/details/32110de5fa6651398632ec116e93577d/), [Yan Geneformer scGPT Scaling Laws BMC Genomics 2026](https://consensus.app/papers/details/db23619e10075c0eb0957368f25ba7de/), [Dimitrov Single-Cell Mechanistic Nature Reviews Genetics 2026](https://consensus.app/papers/details/4c9a5a9396a85b9797d6e1f0ecd4286b/)*

*#SingleCell #FoundationModel #CellxPert #MCMC #MetropolisHastings #InferenceTime #PerturbationPrediction #Demir #LoRA #FineTuning #MERFISH #Yan #BMCGenomics #ScalingLaws #Geneformer #scGPT #SummaryStatistics #Dimitrov #NatureReviewsGenetics #Mechanistic #CausalInference #Disentanglement #OptimizingDay #Perturbation #MultiOmics #OutOfDistribution #CellTypeAnnotation #ISP #GeneRegulatoryNetwork*

---

### Post 6: FDA/규제 — 2026년 FDA Pipeline 52개 Novel Drugs와 2025년 45개 신약 승인 분석

📋 **[FDA/규제] 2026년 FDA novel drug pipeline 52개 예상(Dean AJHP 2026) + 2025년 FDA 45개 신약 + 4개 CGT 승인 분석(Kayki-Mutlu Naunyn-Schmiedeberg 2026) + 2026-2027년 60개 novel drugs 예상(Joseph AJHP 2026): FDA pipeline 최적화 단계 동시 확인**

FDA/규제의**최적화 단계**가 출처에서 동시에 확인된다[13][14][15].

**2026년 FDA Novel Drug Pipeline: 52개 예상[13]**
Collin Dean et al.(AJHP 2026)의 review는 2026년 FDA novel drug approvals pipeline을 예측한다. **52개 novel drugs**: FDA 승인 대기 중. **치료 영역**: rare/inherited genetic disorders, immunologic/inflammatory diseases, targeted oncology, gene therapies. **Health-system pharmacists 역할**: formulary management, resource allocation, clinical programs optimization. ** Pipeline 강화**: novel therapies가 hospital and clinic에서 significant clinical and financial impact 예상. 핵심: 2026년 FDA 52개 novel drugs 예상 — pipeline 최적화 단계.

**2025년 FDA 45개 신약 + 4개 CGT 승인 분석: Oncology 중심 + mRNA/Gene/Cell Therapy 성장[14]**
Gizem Kayki-Mutlu et al.(Naunyn-Schmiedeberg's Archives of Pharmacology 2026)의 review는 2025년 FDA drug approvals를 분석한다. **45개 new drugs + 4개 CGTs**: 총 49개 new medical therapies 승인. **Oncology가 most frequent**: 치료 영역 중 가장 많음. **추세**: ever smaller subtypes of malignancies + rarer malignancies 표적화. **6년간 안정적 수준**: first-in-indication 약 10%, first-in-class 약 38%, next-in-class 약 51%. **Orphan indications 50% 이상**: fast track approvals 50% 이상. **치료 형태**: small molecules 60%, mRNA/gene/cell-based therapy 증가세. 핵심: 2025년 FDA 49개 승인 분석 — oncology 중심 + advanced therapy 성장.

**2026-2027년 FDA Pipeline: 60개 Novel Drugs 예상[15]**
R. Joseph et al.(AJHP 2026)의 review는 2026 Q2-2027 Q1 FDA pipeline을 예측한다. **60개 novel drugs**: FDA 승인 대기. **치료 영역**: rare/inherited genetic disorders, immunologic/inflammatory diseases, targeted oncology, gene therapies. **의료계 영향**: pharmacists의 역할 강화 — pipeline monitoring, formulary management. 핵심: 2026-2027년 FDA 60개 novel drugs 예상 — pipeline 최적화 단계 확대.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Staton Cancer Biology Therapy**으로 **CAPItello-281 biomarker-guided FDA approval**을, **Morimoto Regenerative Therapy**으로 **ALS three converging approaches**를, **Del Toro Runzer Bioactive Materials**으로 **BMP-7 mRNA 골 재생**을 제시했다면, 오늘은 **Dean AJHP**으로 **2026년 52개 novel drugs pipeline 예상**을(pipeline 현황), **Kayki-Mutlu Naunyn-Schmiedeberg**으로 **2025년 49개 승인 분석 oncology 중심 + advanced therapy 성장**을(2025년 실적), **Joseph AJHP**으로 **2026-2027년 60개 novel drugs 예상**을(future pipeline) 동시에 제시한다. Expanding(8/20) → pipeline 현황 + 실적 분석 + future 예상 Optimizing(8/25).

실무 함의: 규제 기획팀에서 Kayki-Mutlu et al.의 2025년 승인 분석을 참조하여 2026년 regulatory strategy를 수립해야 한다.

*출처: [Dean FDA Pipeline AJHP 2026](https://consensus.app/papers/details/780421396729574383a4c7cfcb479acb/), [Kayki-Mutlu FDA 2025 Approvals Naunyn-Schmiedeberg's Archives of Pharmacology 2026](https://consensus.app/papers/details/b602023750335ba5bf29c1dfbf3e936f/), [Joseph FDA Pipeline AJHP 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/)*

*#FDA #Dean #AJHP #2026Pipeline #52Drugs #KaykiMutlu #NaunynSchmiedeberg #2025Approvals #45Drugs #4CGTs #49Total #Oncology #OrphanIndications #FastTrack #mRNA #GeneTherapy #CellTherapy #SmallMolecules #Joseph #AJHP #Pipeline2026 #2027 #OptimizingDay #PipelineOptimization #TargetedOncology #RareDisease #Immunology #Pharmacists #Formulary*

---

### Post 7: Spatial Transcriptomics — Spatial Ecotypes cfDNA Deep Learning과 Tumor Microenvironment 최적화

🗺️ **[Spatial Transcriptomics] Spatial ecotypes(SEs)가 cfDNA deep learning으로 immunotherapy response 예측 가능성 확인(Zhang Nature 2026) + Pan-cancer 12개 암종 373개 샘플에서 56개 LCPs + 13개 niches 발견으로 TSME 체계적 분석(Li Cell Reports Medicine 2026) + Spatial omics의 TME dynamics profiling 통합 분석(Nguyen Clinical & Translational Immunology 2026): spatial transcriptomics의 최적화 단계 동시 확인**

Spatial Transcriptomics의**최적화 단계**가 출처에서 동시에 확인된다[16][17][18].

**Spatial Ecotypes: cfDNA Deep Learning으로 Immunotherapy Response 예측[16]**
Wubing Zhang et al.(Nature 2026)의 연구는 spatial ecotypes(SEs) framework를 제시한다. **9개 SEs 동정**: 10 million+ single-cell and spot-level spatial transcriptomes 통합 분석. **Broad conservation**: human carcinomas and melanomas에서 보편적. **각 SE의 고유 biology**: geospatial features + clinical outcome associations. **Immunotherapy response 예측**: cfDNA deep learning으로 SE levels 측정 가능. **Melanoma 100명에서 검증**: immunotherapy response와 striking associations 확인. **cfDNA recoverable**: SE levels가 plasma cell-free DNA에서 검출 가능. 핵심: Spatial ecotypes cfDNA deep learning으로 immunotherapy response 예측 — liquid biopsy 최적화 적용.

**Pan-Cancer TSME 체계적 분석: 56개 LCPs + 13개 Niches[17]**
Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 12개 암종 373개 샘플에서 tumor spatial microenvironment(TSME)를 분석한다. **56개 Local Cellular Programs(LCPs)**: 종양 미세환경의 지역적 세포 프로그램. **13개 Recurrent Niches**: niche-shared와 niche-specific ligand-receptor interactions 확인. **위치 의존성**: tumor cells와 macrophages의 gene expression이 위치에 크게 의존. **Niche 4(Macrophage-Tumor colocalization)**: poor prognosis + immunotherapy resistance 상관관계. **Niche 11(Macrophage-Immune colocalization)**: better survival + treatment response 예측. 핵심: Pan-cancer TSME 체계적 분석으로 56개 LCPs + 13개 niches 발견 — tumor microenvironment 최적화 전략 수립.

**Spatial Omics TME Dynamics Profiling: 통합 분석[18]**
Hao Nguyen et al.(Clinical & Translational Immunology 2026)의 review는 spatial omics로 TME dynamics를 profiling하는 방법을 분석한다. **ST + SP revolution**: intact tissue에서 RNA와 단백질 분포 mapping. **dynamic TME interactions**: physiology에서 disease tissue까지. **AI integration의 가치**: biological and translational applications에서 promise. **현재 도전**: cross-platform integration, data standardisation, computational scalability, AI model interpretability. 핵심: Spatial omics TME dynamics profiling 통합 분석 — 최적화 단계의 기술적 도전 인식.

**8월 20일 Expanding Day vs 오늘의 차별점**: 8/20이 **Koppensteiner Oncoimmunology**으로 **CAF-T cell adenosine axis NSCLC biomarker**를, **Lang Cancer Biology Therapy**으로 **CD3+ B cells DLBCL microenvironment**를, **Walberg Gut Microbes**로 **bacterial LPS-CRC immune crosstalk**를 제시했다면, 오늘은 **Zhang Nature**으로 **spatial ecotypes cfDNA deep learning immunotherapy response 예측**을(liquid biopsy 최적화), **Li Cell Reports Medicine**으로 **pan-cancer 56 LCPs + 13 niches 체계적 분석**을(microenvironment 최적화), **Nguyen Clinical & Translational Immunology**로 **spatial omics TME dynamics 통합 분석**을(기술 통합)을 동시에 제시한다. Expanding(8/20) → liquid biopsy 적용 + microenvironment 체계적 분석 + 기술 통합 Optimizing(8/25).

실무 함의: spatial transcriptomics 연구팀에서 Zhang et al.의 spatial ecotypes framework를 분석하여 immunotherapy response prediction strategy를 수립해야 한다.

*출처: [Zhang Spatial Ecotypes cfDNA Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Li Pan-Cancer TSME Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Nguyen Spatial Omics TME Clinical & Translational Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/)*

*#SpatialTranscriptomics #Zhang #SpatialEcotypes #Nature #cfDNA #DeepLearning #Immunotherapy #Response #Melanoma #Li #CellReportsMedicine #TSME #PanCancer #12CancerTypes #373Samples #56LCPs #13Niches #Niche4 #Niche11 #Macrophage #Tumor #Nguyen #ClinicalTranslationalImmunology #SpatialOmics #TME #DynamicProfiling #OptimizingDay #LiquidBiopsy #SpatialEcology #CellularPrograms #NicheSpecific #LigandReceptor #Prognosis #Resistance #TreatmentResponse*

---

### Post 8: 오늘의 요약 — Optimizing(최적화 Day) 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

8/25(Optimizing)의 핵심: Transitioning(8/24)된 기술들이 **산업화 조건 충족 후 자원 최적화·효율화·정밀화로 전환(Optimizing)하는 날**이었다.

**1. LuT Lipids Tripod-Like Lung-Targeting 90% Selectivity 달성(Tian Nature Biomedical Engineering 2026)**: 444개 LuT lipids 중 lead 1A7B13이 25.5배 mRNA 전달 개선 + 9.2배 CRISPR-Cas9 editing 개선 + 90% 폐 선택성 — Organ-Targeting LNP 최적화의里程碑. [Tian Nature Biomedical Engineering 2026]

**2. CICS Single-Particle LNP Payload Distribution Gene Editing Potency 상관관계 정량화(Truong Molecular Therapy 2026)**: co-encapsulated 50.7-60.4%에서 1.5배 potency 차이(55.4% vs 36.3% indels) — delivery quality optimization의 정밀화. [Truong Molecular Therapy 2026]

**3. CellxPert Inference-Time MCMC Steering Perturbation Prediction 정밀화(Demir ArXiv 2026)**: MERFISH + imaging mass cytometry 통합 + MCMC steering로 OOD artifacts 완화 — multi-omics foundation model inference optimization. [Demir ArXiv 2026]

**4. Spatial Ecotypes cfDNA Deep Learning Immunotherapy Response 예측(Zhang Nature 2026)**: 9개 spatial ecotypes + melanoma 100명에서 cfDNA deep learning immunotherapy response striking associations — liquid biopsy 최적화 적용. [Zhang Nature 2026]

**5. AlphaFold Mutation Invariance Template-Based Pattern Matching 의존성 문제 확인(Feldman Computational Biotechnology 2026)**: 40% 잔기 치환에도 구조 불변 + confidence metrics 35% 이하에서만 정확 — de novo protein design 해석 주의 필요. [Feldman Computational Biotechnology 2026]

**6. 2026년 FDA 52개 Novel Drugs Pipeline 예상(Dean AJHP 2026)**: rare diseases + oncology + gene therapies + immunology — pipeline 최적화 단계. [Dean AJHP 2026]

**8월 26일 전망**: Optimizing된 기술들의 자원 효율화·정밀 예측·최적 배치 속도가 핵심 변수. 특히 LuT lipids의 lung-targeting 임상 적용, CICS quality control 표준화, spatial ecotypes cfDNA validation이 관전.

*출처: [Tian LuT Lipids Nature Biomedical Engineering 2026](https://consensus.app/papers/details/58273e5a294453e4b49033311d6f6192/), [Truong CICS LNP Molecular Therapy 2026](https://consensus.app/papers/details/31a186a2826b5b9f9eb8c87ed71a040c/), [Ciganek LNP Immune Cell Engineering Materials Today Bio 2026](https://consensus.app/papers/details/48353b932e435fcc94a00ac93469e299/), [Mao AI Drug Discovery Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Singh AlphaFold Protein-Ligand Current Opinion 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Dean FDA Pipeline AJHP 2026](https://consensus.app/papers/details/780421396729574383a4c7cfcb479acb/), [Feldman AlphaFold Mutation Invariance Computational Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Kinde AlphaFold Applications Results Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/), [Demir CellxPert ArXiv 2026](https://consensus.app/papers/details/32110de5fa6651398632ec116e93577d/), [Yan Geneformer scGPT Scaling BMC Genomics 2026](https://consensus.app/papers/details/db23619e10075c0eb0957368f25ba7de/), [Dimitrov Single-Cell Mechanistic Nature Reviews Genetics 2026](https://consensus.app/papers/details/4c9a5a9396a85b9797d6e1f0ecd4286b/), [Kayki-Mutlu FDA 2025 Naunyn-Schmiedeberg 2026](https://consensus.app/papers/details/b602023750335ba5bf29c1dfbf3e936f/), [Zhang Spatial Ecotypes Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Li Pan-Cancer TSME Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Nguyen Spatial Omics Clinical Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/)*

*#OptimizingDay #Summary #Tian #LuTLipids #TripodLike #Truong #CICS #PayloadDistribution #Demir #CellxPert #MCMC #Yan #ScalingLaws #Dimitrov #Mechanistic #Zhang #SpatialEcotypes #cfDNA #Feldman #MutationInvariance #Dean #FDA2026 #52Drugs #KaykiMutlu #2025Approvals #Li #TSME #Niches #Nguyen #SpatialOmics #Optimizing #Transitioning #ResourceOptimization #PrecisionDelivery #PerturbationPrediction #OrganTargeting #LNPDesign #cfDNA #LiquidBiopsy #Immunotherapy #ProteinAI #ConfidenceMetrics #TemplateBased #PatternMatching #ClinicalTranslation #Pipeline*

---

## Sources

[1] [Tian et al. — 'Tripod-like' lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing. Nature Biomedical Engineering 2026](https://consensus.app/papers/details/58273e5a294453e4b49033311d6f6192/)
[2] [Truong et al. — Messenger RNA and Guide RNA Distributions in Lipid Nanoparticles Impact Gene-editing Efficiency In Vivo. Molecular Therapy 2026](https://consensus.app/papers/details/31a186a2826b5b9f9eb8c87ed71a040c/)
[3] [Ciganek et al. — Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles. Materials Today Bio 2026](https://consensus.app/papers/details/48353b932e435fcc94a00ac93469e299/)
[4] [Mao et al. — Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)
[5] [Singh et al. — More Protein-Ligand data is needed for AlphaFold-like Models to enable drug discovery. Current Opinion in Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)
[6] [Dean et al. — Recent and anticipated novel drug approvals (1Q 2026 through 4Q 2026). AJHP 2026](https://consensus.app/papers/details/780421396729574383a4c7cfcb479acb/)
[7] [Feldman et al. — Adversarial Sequence Mutations in AlphaFold and ESMFold Reveal Nonphysical Structural Invariance, Confidence Failures, and Concerns for Protein Design. Computational and Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/)
[8] [Kinde et al. — Harnessing AlphaFold: Applications in Disease Understanding, Drug Discovery, and Vaccine Design. Results in Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/)
[9] [Singh et al. — More Protein-Ligand data is needed for AlphaFold-like Models to enable drug discovery. Current Opinion in Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/)
[10] [Demir et al. — CellxPert: Inference-Time MCMC Steering of a Multi-Omics Single-Cell Foundation Model for In-Silico Perturbation. ArXiv 2026](https://consensus.app/papers/details/32110de5fa6651398632ec116e93577d/)
[11] [Yan et al. — Evaluating the learnability of single-cell large language models on multiple tasks. BMC Genomics 2026](https://consensus.app/papers/details/db23619e10075c0eb0957368f25ba7de/)
[12] [Dimitrov et al. — Interpretation, extrapolation and perturbation of single cells. Nature Reviews Genetics 2026](https://consensus.app/papers/details/4c9a5a9396a85b9797d6e1f0ecd4286b/)
[13] [Dean et al. — Recent and anticipated novel drug approvals (1Q 2026 through 4Q 2026). AJHP 2026](https://consensus.app/papers/details/780421396729574383a4c7cfcb479acb/)
[14] [Kayki-Mutlu et al. — A year in pharmacology: new drugs approved by the US food and drug administration in 2025. Naunyn-Schmiedeberg's Archives of Pharmacology 2026](https://consensus.app/papers/details/b602023750335ba5bf29c1dfbf3e936f/)
[15] [Joseph et al. — Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027). AJHP 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/)
[16] [Zhang et al. — Non-invasive profiling of the tumour microenvironment with spatial ecotypes. Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/)
[17] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)
[18] [Nguyen et al. — Spatial omics for profiling the dynamic tumor microenvironment. Clinical & Translational Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/)